Cargando…

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

There is individual variation in the course of disease development and response to therapy of patients with chronic lymphocytic leukemia (CLL). Novel treatment options for CLL include a new generation of purine analogs, antibodies and inhibitors of specific cell signaling pathways, which typically i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogalińska, Małgorzata, Góralski, Paweł, Błoński, Jerzy Z., Robak, Paweł, Barciszewski, Jan, Koceva-Chyła, Aneta, Piekarski, Henryk, Robak, Tadeusz, Kilianska, Zofia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403444/ https://www.ncbi.nlm.nih.gov/pubmed/28454364 http://dx.doi.org/10.3892/ol.2017.5725

Ejemplares similares

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors
por: Kubczak, Małgorzata, et al.
Publicado: (2019)

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
por: Gora-Tybor, Joanna, et al.
Publicado: (2003)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

Atypical Chronic Lymphocytic Leukemia—The Current Status
por: Robak, Tadeusz, et al.
Publicado: (2023)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Application of New Drugs in Chronic Lymphocytic Leukemia
por: Robak, Tadeusz
Publicado: (2010)

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
por: Robak, T, et al.
Publicado: (1999)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
por: Robak, Tadeusz, et al.
Publicado: (2009)

Decreased activity of butyrylcholinesterase in blood plasma of patients with chronic obstructive pulmonary disease
por: Sicinska, Paulina, et al.
Publicado: (2016)

Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (1999)

Puma, a critical mediator of cell death — one decade on from its discovery
por: Hikisz, Paweł, et al.
Publicado: (2012)

Doxyl Nitroxide Spin Probes Can Modify Toxicity of Doxorubicin towards Fibroblast Cells
por: Czepas, Jan, et al.
Publicado: (2020)

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Puła, Anna, et al.
Publicado: (2023)

Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity.
por: Robak, E, et al.
Publicado: (2001)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia
por: Hartman, Mariusz L., et al.
Publicado: (2013)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
por: Mikulski, Damian, et al.
Publicado: (2022)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
por: Chanan-Khan, A, et al.
Publicado: (2017)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Book review: Safety of Biologics Therapy
por: Robak, Tadeusz
Publicado: (2017)

Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia
por: Karabon, Lidia, et al.
Publicado: (2016)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Paweł, et al.
Publicado: (2020)

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Pawel, et al.
Publicado: (2021)

Anticancer and Antibacterial Activity Studies of Gold(I)-Alkynyl Chromones
por: Hikisz, Paweł, et al.
Publicado: (2015)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020)

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
por: Urbańska-Ryś, Halina, et al.
Publicado: (2003)

Safety and Tolerability of Antibody-Drug Conjugates in Cancer
por: Wolska-Washer, Anna, et al.
Publicado: (2019)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus
por: Robak, Ewa, et al.
Publicado: (2006)

The Expression of the SLIT–ROBO Family in Adult Patients with Acute Myeloid Leukemia
por: Gołos, Aleksandra, et al.
Publicado: (2019)

Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
por: Klonowska-Szymczyk, Agnieszka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pn6349dhn0proecpjngn5v78rs